Albumin market seen reaching $10.62 billion by 2030
The albumin market is projected to grow from $7.81 billion in 2026 to $10.62 billion by 2030, driven by diabetes prevalence, biopharmaceutical demand and recombinant albumin development. North America led in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.
Why it matters: - Albumin is used in diagnostics, drug delivery, research and treatment monitoring, so market growth tracks broader demand in healthcare and life sciences. - Rising diabetes cases are expanding the need for kidney-function monitoring, where albumin plays an important clinical role. - The market outlook points to more use of recombinant albumin, which could help ease reliance on plasma-derived supply.
What happened: - The Business Research Company projected the global albumin market will rise from $7.81 billion in 2026 to $10.62 billion by 2030. - The forecast implies an 8.0% compound annual growth rate through 2030. - The company said the market reached $7.16 billion in 2025 and grew to $7.81 billion in 2026. - North America held the largest regional share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report is titled The Business Research Company’s Albumin Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - A free sample is available here. - The full report is available here.
The details: - Past growth was fueled by constraints in plasma-derived albumin supply, more liver disease and burn cases, wider use in diagnostic kits, rising biopharmaceutical R&D and early adoption in laboratory and research settings. - Forecast growth is supported by advances in recombinant albumin technology, expanding personalized medicine use, broader adoption in drug delivery systems, growth in biopharmaceutical manufacturing and higher investment in therapeutic and cosmetic sectors. - The report expects more use of human serum albumin in treatments. - The report also points to broader applications in drug formulations and vaccines. - The company expects higher adoption of recombinant albumin in biopharma. - The report highlights growing use in cell culture and diagnostic kits. - Albumin is a protein found in blood plasma, serum, muscle tissue, egg whites, milk and some animal and plant substances. - Albumin is described as simple in structure, heat-coagulable and water-soluble. - Albumin helps maintain fluid balance and transports hormones, vitamins and enzymes. - In April 2025, the International Diabetes Federation said about 589 million adults and 9.5 million people with type 1 diabetes were affected in 2024, including 1.9 million children and adolescents. - The International Diabetes Federation projected that figure would rise to 853 million by 2050.
Between the lines: - The forecast suggests albumin demand is tied not just to one disease area, but to a mix of chronic disease care, diagnostics and biopharma manufacturing. - The focus on recombinant albumin signals a broader industry push toward more scalable and potentially less supply-constrained production. - The diabetes data reinforces why albumin remains relevant in routine clinical monitoring, not only specialized therapy.
What's next: - The market is expected to keep expanding as biopharmaceutical manufacturing scales and albumin use spreads across more formulations and research tools. - Regional growth should remain uneven, with North America retaining leadership and Asia-Pacific adding pace. - The report’s 2026 edition adds market attractiveness scoring, TAM analysis, a company scoring matrix, Excel forecasting dashboards, hotspot infographics and updated trend analysis.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
The Asia Gazette
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.